Press Release

CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *